Candesartan Cilexetil

CHEMBL1014 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
610.7 g/mol
LogP
7.0
Phase
4

A prodrug of candesartan that is rapidly converted to the active drug after oral absorption. It is used to treat hypertension and heart failure with reduced ejection fraction. It offers the benefit of once-daily dosing for long-term cardiovascular protection.

น้ำหนักโมเลกุล

610.7000 g/mol

LogP

7.00

TPSA

143.00 Ų

Lipinski RO5

ไม่ผ่าน

ด้านการรักษา

กลไกการออกฤทธิ์

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1

InChI

InChI=1S/C33H34N6O6/c1-3-42-32-34-28-15-9-14-27(31(40)43-21(2)44-33(41)45-24-10-5-4-6-11-24)29(28)39(32)20-22-16-18-23(19-17-22)25-12-7-8-13-26(25)30-35-37-38-36-30/h7-9,12-19,21,24H,3-6,10-11,20H2,1-2H3,(H,35,36,37,38)

Molecular Formula

C33H34N6O6

HBD / HBA

1 / 10

พันธะที่หมุนได้

13

อะตอมหนัก

45

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

A prodrug of candesartan that is rapidly converted to the active drug after oral absorption. It is used to treat hypertension and heart failure with reduced ejection fraction. It offers the benefit of once-daily dosing for long-term cardiovascular protection.

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Yes, Candesartan Cilexetil is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1014. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 2540. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.